Abstract Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility values in AMD. We describe how utility values have been used in healthcare decision making and provide guidance on the choice of utility values for future economic evaluations for AMD. Literature was searched using PubMed, and health technology assessments (HTA) were searched using HTA agency websites to identify articles reporting utility values or approaches to derive utility values in AMD and articles applying utilities for use in healthcare decision making relating to treatments for AMD. A total of 70 studies qualified for data extraction, 22 of which were classified as containing utility values and/or elicitation methods, and 48 were classified as using utility values in decision making. A large number of studies have elicited utility values for AMD, although those applied to decision making have focused on a few of these. There is an appreciation of the challenges in the measurement and valuation of health states, with recent studies addressing challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires and utility in the worse-seeing eye. We would encourage careful consideration when choosing utility values in decision making and an explicit critique of their applicability to the decision problem.
Background
Age-related macular degeneration (AMD) is a common cause of visual impairment in older adults. Untreated, the disease leads to the progressive loss of central vision and affects the ability to perform daily activities such as recognising faces and reading [1] .
The disease covers two forms with different underlying causes. Dry AMD begins with drusen in the macular (agerelated maculopathy), which may develop into geographic atrophy. There is currently no treatment for dry AMD. Wet (neovascular) AMD is caused by abnormal blood vessel growth. A number of treatments have become available for neovascular AMD over the past 10 years: first verteporfin photodynamic therapy (vPDT) and later a number of antivascular endothelial growth factors (anti-VEGFs), including ranibizumab (Lucentis Cost-utility analysis has been widely used to assess the relative value of these interventions. A recent review of economic models comparing treatments for AMD identified 36 studies, of which all but three reported costs per quality-adjusted life-year (QALY) [2] .
QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are anchored so that 1 is perfect health and 0 is equivalent to the state of death. Multiplying time in a health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 QALY [3] . The term 'utility' in cost-utility analysis and its theory is based on von Neumann-Morgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a rational individual ought to behave, is that utility scores represent the strength of an individual's preference when faced with uncertainty for a given outcome, in this case a health state [4] .
Utilities have been identified as major sources of uncertainty within economic models, both in terms of the sensitivity of model outputs to the choice of utility values and in terms of the methods by which utility values are elicited [2] .
The importance of utility values in economic evaluations of interventions for AMD stems from the nature of the condition: the disease is characterised by the progressive loss of central vision, which severely limits the ability to perform daily activities and consequently has a major effect on quality of life. There have been two relevant reviews to date covering utility values in AMD. Pearson et al. [5] systematically reviewed utility values specific to wet AMD and evaluated these against the UK National Institute for Health and Care Excellence (NICE) reference case. They recommended the time trade-off (TTO) and Health Utilities Index Mark 3 (HUI-3) for use in economic evaluations based on the correlation of these measures with visual acuity. Poku et al. [6] systematically reviewed articles reporting the relationship between visual acuity and utility across AMD, diabetic retinopathy (DR) and diabetic macular oedema (DMO). They found that self-reported TTO was most strongly associated with visual acuity and that utility values had a higher association with the betterseeing eye than the worse-seeing eye.
Also of note, Tosh et al. [7] reviewed generic preference-based measures of health-related quality of life (HRQoL) in visual disorders, finding that the performance of the EuroQol 5-Dimension (EQ-5D) instrument was mixed, and that more head-to-head comparisons were needed between the EQ-5D, the Short-Form 6 Dimensions (SF-6D) and the HUI-3.
This review aims to identify and critique published utility values and methods for eliciting de novo utility values in AMD. The review describes how utility values have been used in economic models and healthcare decision making and provides guidance for the choice of utility values in future economic evaluations for AMD.
Methods
We conducted a search in PubMed to determine the approaches that have been used to derive utility values in AMD and how utility values have been used in healthcare decision making relating to treatments for AMD. The search was supplemented with health technology assessment (HTA) agency websites to support the latter aim.
Title and abstracts were searched in PubMed on 3 January 2016. No date or language restrictions were applied to the searches. Terms covering AMD and utility were combined using the following search strategy: [ A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) scheme (Table 1) illustrates the inclusion/exclusion process. Of the 206 studies identified, 113 were excluded after review of abstracts and titles. Reasons for exclusion included the topic not relating to utility, the disease not covering AMD, there being no primary data (e.g. letter or review) and the language not being English. After full-text review, a further 23 studies were excluded because the topic did not relate to utility, the type of article was a letter or review with no primary data or the study was a duplicate.
Included studies were classified into those reporting utilities (utility sets or methods to derive utility sets) and those applying utilities to decision making (economic evaluations and HTAs). Two data extraction sheets were used to classify the data from the studies. The first extraction sheet recorded key methodological parameters such as elicitation technique, geography and sample for studies reporting utility sets or methods to derive utility sets. The second extraction sheet recorded utility values used in the base case for economic evaluations and HTAs.
Results
A total of 70 studies were selected for data extraction, 22 of which were classified as containing utility values and/ or elicitation methods relevant to AMD; 48 were classified as using utility values in decision making. A small number of the latter also collected de novo utilities. Tables 2 and 3 summarise the key components of the included studies.
Utility Values and Elicitation Methods
The majority of utility values identified were classified by health states. This is likely because the majority of economic models for AMD are health state transition models. The health states tend to be defined by visual function parameters, chiefly visual acuity, although contrast sensitivity has also been associated with utility, and research has suggested that contrast sensitivity may be better correlated with utility than visual acuity [8, 9] .
Early studies focused on the elicitation of utilities directly from patients. For example, Brown et al. [10] elicited utilities from patients using the TTO and standard gamble (SG) methods. Utilities have also been elicited via tariffs of preference-based questionnaires [8] , from healthy volunteers via simulation contact lenses [11] and from ophthalmologists [12] .
The most common elicitation method was the TTO, which was used in 16 of the 22 studies. Anchors of perfect health/death and perfect vision/blindness have been used to elicit utilities (Table 2) . It has been shown that different utility values can be obtained depending on the anchor. For example, Au Eong et al. [13] obtained a mean utility of 0.91 using the SG anchored to blindness and 0.86 using the SG anchored to death.
Samples for deriving utility estimates ranged in size depending on the research question, with the largest being a cohort of 1829 patients with AMD who completed the SF-36 as part of the Verteporfin Photodynamic Therapy Cohort Study [14] (Table 2) .
Utilities are available for a number of countries ( Table 2 ). The USA and the UK were the most common countries for utilities, which is indicative of the location of prominent health economic research groups but may also be a function of an English language search strategy.
Lee et al. [15] found considerable variation in the utility values reported, with values differing by as much as twofold between studies. A number of studies used several methods and presented different utility values by method, with several studies particularly focussing on the differences between elicitation methods. Yanagi et al. [16] found that TTOderived utilities correlated more strongly with better-seeing eye visual acuity than SG-derived utilities in a study of Japanese patients. Stein et al. [17] investigated the impact of eliciting utilities for AMD health states from different groups and found that patients rated their health more severely than clinicians or the general population using the TTO.
Some studies highlighted the challenges of using generic preference-based questionnaires to derive utilities in AMD and proposed recommendations and/or methodological improvements. Espallargues et al. [8] elicited utilities for several generic preference-based questionnaires and the TTO, concluding that the HUI-3 would be the preferred measure. One study provided a mapping algorithm to derive utilities from the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25). Payakachat et al. [18] predicted EQ-5D utility values from the NEI-VFQ 25 in a population of patients with wet AMD.
A number of papers have addressed the multi-factorial considerations of utility in AMD. Most utility values were associated with the better-seeing eye. Utility values can vary considerably depending on whether the better-seeing or worse-seeing eye is affected and whether utility values for the worse-seeing eye are available [19] . Skalicky et al. [20] investigated the impact of ocular co-morbidities on utility, chiefly AMD in patients with glaucoma. Adverse events have been elicited including event-based utility decrements. For example, Mowatt et al. [21] applied utility weights based on Brown et al. [10] for health states and then decrements for adverse events including cataract, endophthalmitis, retinal detachment and uveitis. 
Utility Values in Decision Making
All but one of the identified studies that applied utilities to decision making took the form of cost-utility analyses. One study compared QALYs without including costs: Kim et al. [22] investigated the impact of PDT on patients with AMD in Korea.
Most studies applied utilities from Brown et al. [10] based on the TTO approach in a sample of patients with AMD (Table 3) . These utility values were derived from a mixed population of wet and dry AMD, whereas the decision problem in many papers was often for a specific form of AMD. Studies assessed a number of treatments, including anti-VEGFs, PDT and screening, although we found no trend in terms of applying different utility weights based on the intervention under consideration. Nor was there a trend to apply different utility values according to geography of study, despite values being available for several geographies.
Studies found that the choice of utility set could result in very different estimated QALY gains for similar decision problems. Kymes et al. [23] estimated an incremental QALY gain of 1.15 for ranibizumab or bevacizumab for AMD in their report for CADTH compared with NICE's estimates of incremental QALYs of 0.45-0.73, depending upon the scenario [24] . They concluded that the likely reason for the difference was the utility sets used (Espallargues et al. [8] for NICE and Sharma et al. [25] for CADTH), although the two models also varied in other inputs.
Discussion
Utility values have been widely used in decision making in AMD, and the choice of utility values has been frequently highlighted as having a major effect on the results of economic evaluations.
These evaluations have focused on a few utility sets [10] , whereas other utility sets have not been used to date [18] . Such a focus on a limited range of utility sets improves comparability between studies, although the trade-off is to accept the limitations of the utility values used in terms of methodology and sample.
The most frequently used utility values, from Brown et al. [10] , were derived for visual acuity health states from a mixed sample of patients with wet and dry AMD in the USA. While many economic models focused on specific forms of AMD (wet in the case of evaluations of anti-VEGF therapies) and covered different geographies, most economic models applied the utility values from this small sample of US patients with wet and dry AMD.
Some papers sought to provide guidance on utility values, but there is little evidence that this has been followed. Notably, Espallargues et al. [8] concluded that the HUI-3 would be preferred for use in economic evaluations because of its stronger correlation with visual acuity and contrast sensitivity. However, the HUI-3 was rarely used by studies since (or prior to) this publication.
Some articles that contain relevant guidance on utility values in AMD may not have been picked up by the search strategy if they did not mention the condition explicitly. For example, in an attempt to address the insensitivity of generic HRQoL questionnaires in vision disorders, a vision 'bolt-on' was developed for the EQ-5D-3L [26] . The EQ-5D ? V has been valued in the general population, but the questionnaire content is yet to be validated in patients with vision disorders. The focus of this review was utility values for AMD, therefore it did not include articles on other vision disorders, although many of the findings can be applied to vision disorders more broadly.
What makes 'good' utility values? The strength of utility values depends on the context of use. However, a few general guidelines can be given for choosing utility values for any condition, and a few more specific guidelines can be given for AMD.
Generally, the choice of utility value should reflect the perspective of the decision problem. For example, decisions concerning publically funded healthcare systems should apply utility values that represent the preferences of the general population [27] . Utility values are known to vary by geography, so preferences should reflect the geography of the decision problem, where possible. The measurement of health states on which the utility values are Patel et al. [47] Bevacizumab for AMD USA Modified from Brown (2000) Kim et al. [22] PDT for AMD Korea Within study (EQ-5D)
Neubauer et al. [48] Ranibizumab for nAMD Germany Brown (2000) [10] Hodge et al. [49] Pharmacologic management of nAMD Canada Sharma (2000) [25] Neubauer et al. [50] Retinal pigment epithelium and choroid translocation for nAMD Germany, USA Bansback (2007) [9] Grieve et al. [51] Verteporfin PDT for nAMD UK Within study (SF-6D)
Gower et al. [52] Pegaptanib and ranibizumab for nAMD USA Brown (2002) [35] , [79] Hernandez-Pastor et al. [53] Ranibizumab for nAMD Spain Brown (2000) [10] Karnon et al. [54] Screening for AMD UK Espallargues (2005) [8] , Brown (2000) [10] Fletcher et al. [55] Treatments for nAMD Not specified Sharma (2000) [25] Hurley et al. [56] Smoking cessation to prevent AMD USA Brown (2000) [10] Hurley et al. [57] Ranibizumab for nAMD USA Brown (2000) [10] Bojke et al. [58] Screening for AMD UK Brown (2001) [59] Javitt et al. [60] Early treatment of AMD with pegaptanib USA Brown (2000) [10] Earnshaw et al. [61] Hopley et al. [70] Verteporfin PDT for nAMD Australia and UK Brown (2000) [10] Hopley et al. [71] Screening and zinc/antioxidants for AMD Australia and UK Sharma (2000) [25] based should be based on the patient-reported health of subjects who are experiencing the health state in question. For AMD, a number of utility values are available that meet the needs of different geographies and various health states as defined by type of disease (wet or dry AMD) and by levels of visual function. A number of issues remain that are specific to AMD and should be considered when interpreting or applying utility values.
Adaptation
Patients with chronic conditions may adapt to their condition and therefore rate their health state less severely than a member of the community who is unaffected by the condition [28] (a concept known as adaptation). However, evidence indicates that patients with AMD rate their health state more severely than the public or their clinicians, which would run contrary to the theory of adaptation [17] . For these reasons, we urge careful consideration of the choice of patient or general public utility values and note that this will be further influenced by the perspective of the evaluation.
Age and Co-Morbidities
Utility values should be collected on a scale anchored by perfect health and dead [3] . AMD tends to affect older people who may be experiencing one or more other diseases, and the impact of co-morbidities makes the interpretation of absolute utility values challenging. While costutility analysis requires only the change in utility over time, co-morbidities may increase the variability in utilities collected and so require larger sample sizes to collect robust utility sets.
Better-or Worse-Seeing Eye
Whether the presenting eye is the better-or worse-seeing eye is a significant determinant of the impact of the disease on a patient's quality of life. AMD in the better-seeing eye has a greater impact on a patient than AMD in the worseseeing eye, although vision in both eyes can have an independent impact, and this is reflected in the utility values for each eye [29] . Utility values should incorporate the impact of the disease on the patient's daily life, so should account for vision in both eyes and their interaction.
Wet/Dry Age-Related Macular Degeneration
Utility values are available for samples of wet AMD, dry AMD and mixed samples. Generally, the most appropriate utility set will be that which matches the condition in the decision problem. Most, but not all, decision problems have related to treatments for wet AMD because of the emergence of anti-VEGF therapies; therefore, we expected that utility sets using a wet AMD population would have been used most frequently. However, the most frequently used utility sets were from a mixed sample [10] .
Visual Function
Most economic models are based on visual function, with visual acuity being the most common measure. Utility values are most frequently available for visual acuity. Utility values are also available for contrast sensitivity, although the potential to use these in economic evaluations is limited by the lack of outcomes data collected on the parameter in trials or routine practice. The choice of visual function parameter should be driven by an understanding of the association between visual function and utility as well as the availability of that parameter in the dataset of interest.
Conclusion
There is a large body of literature describing utility values in AMD. An appreciation of the challenges in the measurement and valuation of health states is evident from the papers identified in this review, with recent studies addressing challenges such as the insensitivity of generic HRQoL questionnaires and utility in the worse-seeing eye.
However, it appears the use of utility values in decision making has not kept pace with these methodological developments, as a small number of utility studies are used.
The choice of utility value should be based on a number of considerations, some positive and others normative. It is unlikely that all can be fully addressed by one utility set, therefore we would encourage careful consideration when choosing utility values in decision making; an explicit critique of their applicability to the decision problem and the impact of alternative utility sets should be presented within sensitivity analysis.
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